{"id":119493,"date":"2021-02-12T16:22:18","date_gmt":"2021-02-13T00:22:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/02\/benevolentai-doses-first-patient-in-atopic-dermatitis-drug-trial"},"modified":"2021-02-12T16:22:18","modified_gmt":"2021-02-13T00:22:18","slug":"benevolentai-doses-first-patient-in-atopic-dermatitis-drug-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/02\/benevolentai-doses-first-patient-in-atopic-dermatitis-drug-trial","title":{"rendered":"BenevolentAI doses first patient in atopic dermatitis drug trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/benevolentai-doses-first-patient-in-atopic-dermatitis-drug-trial.jpg\"><\/a><\/p>\n<p>UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).<\/p>\n<p>Designed and developed using BenevolentAI\u2019s scientific and technical expertise, BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery.<\/p>\n<hr>\n<p>BenevolentAI has dosed the first patient in its clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD). Designed and developed using BenevolentAI\u2019s scientific and technical expertise, BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery. BenevolentAI has dosed the first patient in its clinical trial [\u2026]<\/p>\n","protected":false},"author":542,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-119493","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/119493","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/542"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=119493"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/119493\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=119493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=119493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=119493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}